Ventria Bioscience Invited to Present ExpressTec (TM) at the 4th International Plant-Based Vaccines & Antibodies Conference

ExpressTec™ is a plant-based manufacturing technology that enables safe, affordable, and sustainable production of biologics.

Fort Collins, CO, USA, June 6, 2011 / B3C newswire / – Ventria Bioscience will showcase its ExpressTec™ biomanufacturing technology at the 4^th International Plant-Based Vaccines & Antibodies (PBVA) Conference. Scott Deeter, President and CEO, will present “High Yielding and Scalable Plant-based Recombinant Protein Production in Monocots,” as part of the Facilities and Production plenary session on Friday, June 10^th, 2011. The PBVA conference provides an international forum for the medical, veterinary, and plant biotechnology research communities to discuss the current state-of-the art in plant-based biologics technology and research and development related to new product development.

At the conference, Ventria Bioscience will discuss its experience scaling up a plant-based cGMP manufacturing system to commercial scale exceeding 1,000 kilograms of recombinant protein. To accomplish this scale, Ventria employs its proprietary recombinant protein manufacturing technology called ExpressTec™. ExpressTec™ provides a safe, affordable, and sustainable manufacturing platform that produces target protein yields more than ten times higher than alternative systems.

“Ventria is the first company to commercialize recombinant proteins derived from a plant-based manufacturing system and has proven this technology at large scale,” said Scott Deeter, President and CEO for Ventria Bioscience. “ExpressTec™ achieves protein yields, cost-effectiveness and safety advantages that are the foundation of a portfolio of products that were previously not available to a global customer base.”

About Ventria Bioscience
Ventria Bioscience is the first company to commercialize recombinant proteins derived from a plant-based manufacturing system. Ventria’s technology platform ExpressTec is a safe, affordable and sustainable manufacturing technology that achieves recombinant protein yield that is ten times higher than alternative systems. This advantage means Ventria’s products are accessible to a global customer base. Ventria’s product portfolio includes nine commercial products and several new products in development. Ventria’s products target three markets: human health, cell culture and biomanufacturing, and zoonotic disease.

Contact

Ventria Bioscience
320 E Vine Drive
Fort Collins, CO 80524